Outputs & Publications

We are so grateful for the continued support and participation of all the trial volunteers who have taken part in COV001 and COV002 trials – this has provided critical information on the vaccine’s performance over time. Data from these studies are now being used by drug regulatory authorities around the world (including the MHRA, EMA and WHO) to support emergency authorisation of the use of the Oxford Astra-Zeneca vaccine. The vaccine is the most widely distributed of all Covid19 vaccines with over 550 million doses of the Oxford Astra-Zeneca used in more than 170 countries by July 2021 and tens of thousands of deaths prevented all around the world.

Here in the UK, Public Health England estimates that the national vaccination programme has so far prevented 120,000 deaths and around 230,000 hospitalisations.  This work also shows that the Oxford Astra-Zeneca vaccine remains over 90% effective against hospitalisation caused by the ‘delta’ variant of the virus and is available here: 

https://www.gov.uk/government/publications/covid-19-vaccine-surveillance-report

Emerging data from the Oxford vaccine trials now suggests that antibodies persist in the blood for up to a year even after a single dose of vaccine. In addition, increasing the interval between the first and the second dose from 4 weeks to 12 weeks increases the antibody level after the second vaccination, and further increases are seen with even longer dosing intervals.

A small number of trial participants also received a third dose of the Oxford Astra-Zeneca vaccine at about 30 weeks after their second dose, which was well tolerated and boosted antibody levels above those measured after the second dose.

These findings on antibody persistence, dose interval and booster doses are available here:

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01699-8/fulltext

Some of our trial participants have asked if they need booster doses as they were vaccinated early in the trial or received different dose schedules. The government has currently advised people over 40 years, and those with underlying health conditions that put them at higher risk from coronavirus, should be offered a booster vaccine, and that there is no requirement to boost others, at this stage. There is currently no recommendation that healthy adults under the age of 40 or healthy children should be boosted, following two doses of the vaccine. Mild infection with COVID-19 is now common in double-vaccinated individuals whether or not they have been in trials. When these infections occur, they appear to boost immunity substantially.

Further advice from the JCVI (Joint Committee on Vaccination and Immunisation), the UK body that determines national immunisation, is awaited about whether there will be a further extension of boosting to younger age groups.  

The JCVI advice on 3rd doses of COVID-19 vaccines is available here:

https://www.gov.uk/government/publications/jcvi-statement-september-2021-covid-19-booster-vaccine-programme-for-winter-2021-to-2022/

If you are invited to receive a third dose of a COVID-19 vaccine in the national roll-out, you should go ahead and receive a dose of the vaccine you have been offered. Please contact your study team should you have any queries.

Further information for COVID-19 vaccine trial participants from the National Institute of Health Research can be found here:

https://bepartofresearch.nihr.ac.uk/Vaccine-studies/Latest-vaccine-news/index

We are continuing to work on studies to provide evidence on how boosters or new variant vaccines may strengthen immune responses against COVID-19. These data are being provided to the Government to inform their decision-making.

By continuing with your final few clinic visits and continuing to inform us if you have symptoms of COVID-19, trial volunteers are providing invaluable ongoing data about how long the vaccine offers protection, and whether it offers protection against new strains of the virus.

Once again, we wish to thank all the staff and volunteers who are part of the Oxford COVID-19 vaccine trials,

The Oxford Vaccine Group

Publications

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

Cold Spring Harbor Laboratory

Read

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

New England Journal of Medicine

Read

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial

The Lancet

Read

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

The Lancet

Read

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Nature Medicine

Read

T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial

Nature Medicine

Read

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

The Lancet

Read

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

The Lancet

Read

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

The Lancet

Read